An error occurred retrieving publication content to display, please try again.
Home >> Journals >> Health Technology Assessment >> Page Not FoundPlease choose a page from the navigation or try a website search above to find the information you need.
An asthma self-management plan that advised patients to temporarily quadruple their dose of inhaled corticosteroid reduced asthma exacerbations, with fewer serious adverse events and at lower cost.
{{author}}{{author}}{{($index > metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}}
Tricia McKeever
[Image - ORCID logo], Kevin Mortimer
[Image - ORCID logo], Lucy Bradshaw
[Image - ORCID logo], Rebecca Haydock
[Image - ORCID logo], Ian Pavord
[Image - ORCID logo], Bernard Higgins
[Image - ORCID logo], Samantha Walker
[Image - ORCID logo], Andrew Wilson
[Image - ORCID logo], David Price
[Image - ORCID logo], Mike Thomas
[Image - ORCID logo], Graham Devereux
[Image - ORCID logo], Christopher Brightling
[Image - ORCID logo], Charlotte Renwick
[Image - ORCID logo], Steve Parrott
[Image - ORCID logo], Eleanor Mitchell
[Image - ORCID logo], Lelia Duley
[Image - ORCID logo] & Tim Harrison
[Image - ORCID logo].
Tricia McKeever 1, Kevin Mortimer 2, Lucy Bradshaw 3, Rebecca Haydock 3, Ian Pavord 4, Bernard Higgins 5, Samantha Walker 6, Andrew Wilson 7, David Price 8,9, Mike Thomas 10, Graham Devereux 8, Christopher Brightling 7, Charlotte Renwick 11, Steve Parrott 11, Eleanor Mitchell 3, Lelia Duley 3, Tim Harrison 1,*
1 Respiratory Medicine, Nottingham NIHR Biomedical Research Centre, University of Nottingham, Nottingham, UK
2 Liverpool School of Tropical Medicine, University of Liverpool, Liverpool, UK
3 Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK
4 Respiratory Medicine Unit and Oxford Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford, UK
5 Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
6 Asthma UK, London, UK
7 University of Leicester, Leicester, UK
8 University of Aberdeen, Aberdeen, UK
9 Observational and Pragmatic Research Institute, , Singapore
10 University of Southampton, Southampton, UK
11 University of York, York, UK
* Corresponding author Email: tim.harrison@nottingham.ac.uk
Funding: {{metadata.Funding}}
{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}
https://doi.org/{{metadata.DOI}}
Citation:{{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al. ' : ''}}. {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})
[Image - Crossmark status check]The full text of this issue is available as a PDF document from the Toolkit section on this page.
The full text of this issue is available as a PDF document from the Toolkit section on this page.
Response by Professor Tim Harrison on 1 February 2019 at 1:14 PM
Author response to reader question
Thanks for the question. If patients are on SMART or MART they should not be advised to quadruple their dose because the additional puffs of ICS/LABA taken instead of SABA automatically increases their dose of inhaled steroid and LABA when their symptoms increase. This is the reason patients on SMART or MART were excluded from the study
Response by Mrs Joy Chand on 15 January 2019 at 9:29 AM
quadrupling combined inhalers
If medication is quadrupled and the patient is on a SMART or MART system, could they quadrulple their combined inhalers or would they need to attend surgery to obtain a steroid only inhaler, not sure quadrupleing formetarol would be good?
An error has occurred in processing the XML document
© NIHR 2024